Extension of the approval periods of some active substances

(1)

Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011 (2) sets out the active substances deemed to have been approved under Regulation (EC) No 1107/2009.

(2)

The approval periods of the active substances famoxadone, flumioxazine and metalaxyl-m were extended until 30 June 2019 by Commission Implementing Regulation (EU) 2018/917 (3). Applications for the renewal of the inclusion of the active substances famoxadone, flumioxazin and metalaxyl-m in Annex I to Council Directive 91/414/EEC (4) were submitted in accordance with Article 4 of Commission Regulation (EU) No 1141/2010 (5).

(3)

The approval periods of the active substances alpha-cypermethrin, beflubutamid, benalaxyl, benthiavalicarb, bifenazate, boscalid, bromoxynil, captan, cyazofamid, desmedipham, dimethoate, dimethomorph, ethephon, etoxazole, fenamiphos, fluoxastrobin, folpet, foramsulfuron, formetanate, methiocarb, metribuzin, milbemectin, Paecilomyces lilacinus strain 251, phenmedipham, phosmet, pirimiphos-methyl, propamocarb, prothioconazole and s-metolachlor were extended until 31 July 2019 by Implementing Regulation (EU) 2018/917.

(4)

The approval period of the active substance diuron was extended until 30 September 2019 by Commission Implementing Regulation (EU) 2018/1262 (6).

(5)

The approval period of the active substance tebuconazole will expire on 31 August 2019 (7).

(6)

Applications for the renewal of the approvals of the substances referred to in recitals 3 to 5 were submitted in accordance with Commission Implementing Regulation (EU) No 844/2012 (8).

(7)

Due to the fact that the assessment of the substances has been delayed for reasons beyond the control of the applicants, the approvals of those active substances are likely to expire before a decision has been taken on their renewal. It is therefore necessary to extend their approval periods.

(8)

In view of the aim of the first paragraph of Article 17 of Regulation (EC) No 1107/2009, as regards cases where the Commission is to adopt a Regulation providing that the approval of an active substance referred to in the Annex to this Regulation is not renewed because the approval criteria are not satisfied, the Commission is to set the expiry date at the same date as before this Regulation or at the date of the entry into force of the Regulation providing that the approval of the active substance is not renewed, whichever date is later. As regards cases where the Commission is to adopt a Regulation providing for the renewal of an active substance referred to in the Annex to this Regulation, the Commission will endeavour to set, as appropriate under the circumstances, the earliest possible application date.

(9)

Implementing Regulation (EU) No 540/2011 should therefore be amended accordingly.

(10)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,

(1)

in the sixth column, expiration of approval, of row 35, Famoxadone, the date is replaced by ‘30 June 2020’;

(2)

in the sixth column, expiration of approval, of row 37, Metalaxyl-M, the date is replaced by ‘30 June 2020’;

(3)

in the sixth column, expiration of approval, of row 39, Flumioxazine, the date is replaced by ‘30 June 2020’;

(4)

in the sixth column, expiration of approval, of row 44, Foramsulfuron, the date is replaced by ‘31 July 2020’;

(5)

in the sixth column, expiration of approval, of row 46, Cyazofamid, the date is replaced by ‘31 July 2020’;

(6)

in the sixth column, expiration of approval, of row 83, Alpha-cypermethrin, the date is replaced by ‘31 July 2020’;

(7)

in the sixth column, expiration of approval, of row 84, Benalaxyl, the date is replaced by ‘31 July 2020’;

(8)

in the sixth column, expiration of approval, of row 85, Bromoxynil, the date is replaced by ‘31 July 2020’;

(9)

in the sixth column, expiration of approval, of row 86, Desmedipham, the date is replaced by ‘31 July 2020’;

(10)

in the sixth column, expiration of approval, of row 88, Phenmedipham, the date is replaced by ‘31 July 2020’;

(11)

in the sixth column, expiration of approval, of row 97, S-metolachlor, the date is replaced by ‘31 July 2020’;

(12)

in the sixth column, expiration of approval, of row 99, Etoxazole, the date is replaced by ‘31 July 2020’;

(13)

in the sixth column, expiration of approval, of row 109, Bifenazate, the date is replaced by ‘31 July 2020’;

(14)

in the sixth column, expiration of approval, of row 110, Milbemectin, the date is replaced by ‘31 July 2020’;

(15)

in the sixth column, expiration of approval, of row 141, Fenamiphos, the date is replaced by ‘31 July 2020’;

(16)

in the sixth column, expiration of approval, of row 142, Ethephon, the date is replaced by ‘31 July 2020’;

(17)

in the sixth column, expiration of approval, of row 145, Captan, the date is replaced by ‘31 July 2020’;

(18)

in the sixth column, expiration of approval, of row 146, Folpet, the date is replaced by ‘31 July 2020’;

(19)

in the sixth column, expiration of approval, of row 147, Formetanate, the date is replaced by ‘31 July 2020’;

(20)

in the sixth column, expiration of approval, of row 148, Methiocarb, the date is replaced by ‘31 July 2020’;

(21)

in the sixth column, expiration of approval, of row 149, Dimethoate, the date is replaced by ‘31 July 2020’;

(22)

in the sixth column, expiration of approval, of row 150, Dimethomorph, the date is replaced by ‘31 July 2020’;

(23)

in the sixth column, expiration of approval, of row 152, Metribuzin, the date is replaced by ‘31 July 2020’;

(24)

in the sixth column, expiration of approval, of row 153, Phosmet, the date is replaced by ‘31 July 2020’;

(25)

in the sixth column, expiration of approval, of row 154, Propamocarb, the date is replaced by ‘31 July 2020’;

(26)

in the sixth column, expiration of approval, of row 156, Pirimiphos-methyl, the date is replaced by ‘31 July 2020’;

(27)

in the sixth column, expiration of approval, of row 158, Beflubutamid, the date is replaced by ‘31 July 2020’;

(28)

in the sixth column, expiration of approval, of row 163, Benthiavalicarb, the date is replaced by ‘31 July 2020’;

(29)

in the sixth column, expiration of approval, of row 164, Boscalid, the date is replaced by ‘31 July 2020’;

(30)

in the sixth column, expiration of approval, of row 166, Fluoxastrobin, the date is replaced by ‘31 July 2020’;

(31)

in the sixth column, expiration of approval, of row 167, Paecilomyces lilacinus strain 251, the date is replaced by ‘31 July 2020’;

(32)

in the sixth column, expiration of approval, of row 168, Prothioconazole, the date is replaced by ‘31 July 2020’;

(33)

in the sixth column, expiration of approval, of row 192, Diuron, the date is replaced by ‘30 September 2020’;

(34)

in the sixth column, expiration of approval, of row 268, Tebuconazole, the date is replaced by ‘31 August 2020’.